Difference between revisions of "DesignWrite"
(New page: {{Template:Pharma_Portal_badge}} '''DesignWrite''' is a medical communications company providing 'science-based educational programs', 'communication of trends in diagnosis and therapy' a...) |
|||
| Line 2: | Line 2: | ||
'''DesignWrite''' is a medical communications company providing 'science-based educational programs', 'communication of trends in diagnosis and therapy' and 'creative prelaunch and market expansion programs'.<ref>DesignWrite. [http://www.dwrite.com/ DesignWrite]. Accessed 4 March 2010.</ref> | '''DesignWrite''' is a medical communications company providing 'science-based educational programs', 'communication of trends in diagnosis and therapy' and 'creative prelaunch and market expansion programs'.<ref>DesignWrite. [http://www.dwrite.com/ DesignWrite]. Accessed 4 March 2010.</ref> | ||
| + | |||
| + | ==Ghostwriting for Wyeth== | ||
| + | |||
| + | Internal corporate documents show how [[Wyeth]] and DesignWrite worked together to create articles promoting hormone therapy therapy (HRT) from 1997. One article appeared in the [[The American Journal of Obstetrics and Gynecology]] published by [[Elsevier]] as an “Editors’ Choice” feature in 2003 claiming there is '"no definitive evidence" that progestins cause breast cancer and added that hormone users had a better chance of surviving cancer.' <ref>Wilson, D. 12 December 2008. ''The New York Times. '' [http://www.nytimes.com/2008/12/12/business/13wyeth.html Drug Maker Said to Pay Ghostwriters for Journal Articles] Accessed 6 March 2010.</ref> The drug company's HRT drug, [[Prempro]], is a combination of estrogen and progestin.<ref>Wilson, D. 12 December 2008. ''The New York Times. '' [http://www.nytimes.com/2008/12/12/business/13wyeth.html Drug Maker Said to Pay Ghostwriters for Journal Articles] Accessed 6 March 2010.</ref> The publication supporting Prempro was "authored" by Dr. [[John Eden]], but documents show how Wyeth suggested Dr. Eden write the paper and wrote the outline and draft of the manuscript for him.<ref>Wilson, D. 12 December 2008. ''The New York Times. '' [http://www.nytimes.com/2008/12/12/business/13wyeth.html Drug Maker Said to Pay Ghostwriters for Journal Articles] Accessed 6 March 2010.</ref> | ||
==Contact== | ==Contact== | ||
| Line 13: | Line 17: | ||
:Website: http://www.dwrite.com/ | :Website: http://www.dwrite.com/ | ||
| + | |||
| + | ==Resources== | ||
| + | |||
| + | *See [[Ghostwriting]] and [[Excerpta Medica]] | ||
==Notes== | ==Notes== | ||
Latest revision as of 17:08, 6 March 2010
|
This article is part of the Pharma_Portal project of Spinwatch. |
DesignWrite is a medical communications company providing 'science-based educational programs', 'communication of trends in diagnosis and therapy' and 'creative prelaunch and market expansion programs'.[1]
Ghostwriting for Wyeth
Internal corporate documents show how Wyeth and DesignWrite worked together to create articles promoting hormone therapy therapy (HRT) from 1997. One article appeared in the The American Journal of Obstetrics and Gynecology published by Elsevier as an “Editors’ Choice” feature in 2003 claiming there is '"no definitive evidence" that progestins cause breast cancer and added that hormone users had a better chance of surviving cancer.' [2] The drug company's HRT drug, Prempro, is a combination of estrogen and progestin.[3] The publication supporting Prempro was "authored" by Dr. John Eden, but documents show how Wyeth suggested Dr. Eden write the paper and wrote the outline and draft of the manuscript for him.[4]
Contact
- Address:
- 175 Wall Street
- Princeton, NJ 08540 USA
- Tel - 609.924.1116
- Fax - 609.924.6648
- Website: http://www.dwrite.com/
Resources
- See Ghostwriting and Excerpta Medica
Notes
- ↑ DesignWrite. DesignWrite. Accessed 4 March 2010.
- ↑ Wilson, D. 12 December 2008. The New York Times. Drug Maker Said to Pay Ghostwriters for Journal Articles Accessed 6 March 2010.
- ↑ Wilson, D. 12 December 2008. The New York Times. Drug Maker Said to Pay Ghostwriters for Journal Articles Accessed 6 March 2010.
- ↑ Wilson, D. 12 December 2008. The New York Times. Drug Maker Said to Pay Ghostwriters for Journal Articles Accessed 6 March 2010.
